Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jun;39(6):1899-1905.
doi: 10.1007/s10067-020-05004-8. Epub 2020 Mar 4.

Prevalence of Sjögren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry

Leslie R Harrold  1   2 , Ying Shan  3 , Sabrina Rebello  3 , Neil Kramer  4 , Sean E Connolly  5 , Evo Alemao  5 , Sheila Kelly  5 , Joel M Kremer  6 , Elliot D Rosenstein  4
Affiliations
Observational Study

Prevalence of Sjögren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry

Leslie R Harrold et al. Clin Rheumatol. 2020 Jun.

Abstract

The objectives of this analysis were to assess the prevalence of Sjögren's syndrome (SS) associated with rheumatoid arthritis (RA) and to compare baseline characteristics of patients with RA with and without SS. Adult patients with RA from a large observational US registry (Corrona RA), with ≥ 1 visit for assessment of SS status between 22 April 2010 and 28 February 2018, were considered. Patients with RA with versus without SS were compared. SS status was determined from a yes/no variable and reported at enrollment into the Corrona RA registry and follow-up visits. Outcomes were unadjusted prevalence of SS in patients with RA, prevalence of SS by RA disease duration, and baseline characteristics in patients with RA by SS status. Of 24,528 eligible patients, 7870 (32.1%) had a diagnosis of RA and SS. The unadjusted overall rate for SS prevalence in patients with RA was 0.30 (95% confidence interval 0.29, 0.31). SS prevalence increased with increasing RA duration. Patients with RA with versus without SS were more likely to be older, female, and seropositive; had a longer RA duration; higher disease activity; and a higher incidence of comorbidities (hypertension, cardiovascular disease, malignancies, and serious infections), erosive disease, and subcutaneous nodules at index date. Patients with RA and SS had a higher disease burden than those with RA only. The prevalence of SS increased as duration of RA increased. RA with SS was associated with seropositivity, more severe RA, extra-articular manifestations, and comorbidities.Key Points• The overall prevalence of SS among patients with RA was 30%.• The prevalence of SS increased with increasing RA disease duration.• Identifying specific clinical characteristics of patients with RA with SS, such as a greater incidence of extra-articular manifestations and comorbidities, may help clinicians to better characterize this patient population.

Keywords: Observational study; Prevalence; Rheumatoid arthritis; Sjögren’s syndrome.

PubMed Disclaimer

Conflict of interest statement

Leslie R. Harrold is an employee of Corrona, LLC, and a shareholder in Corrona, LLC, and has received grant/research support from Pfizer and consulting fees from AbbVie, Bristol-Myers Squibb, and Roche. Ying Shan and Sabrina Rebello are employees of Corrona, LLC. Neil Kramer has nothing to declare. Evo Alemao, Sean E. Connolly, and Sheila Kelly have stock options/bond holdings in, and are employees of, Bristol-Myers Squibb. Joel Kremer has stock options/bond holdings in, and is an employee of, Corrona, LLC; has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Genentech, Lilly, Regeneron, Sanofi, and Pfizer; and has received grant/research support from AbbVie, Bristol-Myers Squibb, Genentech, Lilly, Novartis, and Pfizer. Elliot D. Rosenstein has received consultancy fees from Amgen and Bristol-Myers Squibb; has received grant/research support from Myriad Genetics and Novartis; and is on speakers’ bureaus for AbbVie, Amgen, and Bristol-Myers Squibb.

Figures

Fig. 1
Fig. 1
Patient disposition. Asterisk indicates yes/no to having SS. Dagger mark indicates after the first capture of SS data in patients with a diagnosis of no SS. RA = rheumatoid arthritis; SS = Sjögren’s syndrome
Fig. 2
Fig. 2
Unadjusted prevalence of SS in patients with RA by duration of disease. Asterisk indicates patients included in analysis = 7077. RA = rheumatoid arthritis; SS = Sjögren’s syndrome
Fig. 3
Fig. 3
Health status as measured by the five domains of the EuroQoL 5-dimension questionnaire: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Health status was measured at the index date. RA = rheumatoid arthritis; SS = Sjögren’s syndrome
See this image and copyright information in PMC

References

    1. Holdgate Nicholas, St.Clair E. Wiliam. Recent advances in primary Sjogren's syndrome. F1000Research. 2016;5:1412. doi: 10.12688/f1000research.8352.1. - DOI - PMC - PubMed
    1. Patel R, Shahane A. The epidemiology of Sjogren’s syndrome. Clin Epidemiol. 2014;6:247–255. doi: 10.2147/CLEP.S47399. - DOI - PMC - PubMed
    1. Mavragani CP, Moutsopoulos HM. Primary versus secondary Sjogren syndrome: is it time to reconsider these terms? J Rheumatol. 2019;46:665–666. doi: 10.3899/jrheum.180392. - DOI - PubMed
    1. He J, Ding Y, Feng M, Guo J, Sun X, Zhao J, Yu D, Li Z. Characteristics of Sjogren's syndrome in rheumatoid arthritis. Rheumatology (Oxford) 2013;52:1084–1089. doi: 10.1093/rheumatology/kes374. - DOI - PubMed
    1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data W Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25. doi: 10.1002/art.23177. - DOI - PubMed

Publication types

Grants and funding